Several groups have explored the possibility of simultaneously reactivating PP2A and inhibiting kinases as a potential therapy to mitigate alterations in tumor suppressor genes and oncogenes implicated in cancer formation [32,36,37,47–49]. Here, PTPA is linked to neoplasm.